CtDNA Based MRD Testing for NAC Monitoring in TNBC
← catalyst calendarSponsored by Personalis Inc. (industry) · PSNL — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
422estimated
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-09 | actual | When the study began enrolling |
| Primary completion | 2025-08-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-01-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- TNBC - Triple-Negative Breast Cancer
- Minimal Residual Disease
Primary outcome
what the primary-completion date above is the date OFEvaluate the correlation of MRD to pCR after NAC in TNBC
measured through study completion, an average of 6 months
Permalink · PSNL's whole pipeline · Catalyst calendar · Every registered study · What changed